

July 16, 2020



## Ligand's Second Quarter Financial Results to be Reported August 3rd

SAN DIEGO--(BUSINESS WIRE)-- **Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)** provided today details of its plans to report second quarter 2020 financial results on August 3, 2020. Ligand's CEO John Higgins, President and COO Matt Foehr, and Executive Vice President and CFO Matt Korenberg will host the conference call.

### Second Quarter 2020 Earnings Conference Call

**What:** Ligand conference call to discuss financial results and provide general business updates

**Date:** Monday, August 3, 2020

**Time:** 8:30 a.m. Eastern time (5:30 a.m. Pacific time)

**Conference Call:** Dial (833) 325-0071 within the U.S.

Dial (720) 405-1612 outside the U.S.  
Conference ID is 1697855

**Webcast:** Live conference call webcast and replay accessible at [www.ligand.com](http://www.ligand.com)

### About Ligand Pharmaceuticals

Ligand is a revenue-generating biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue. Ligand's OmniAb<sup>®</sup> technology platform is a patent-protected transgenic animal platform used in the discovery of fully human mono- and bispecific therapeutic antibodies. The Captisol platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. The Vernalis Design Platform (VDP) integrates protein structure determination and engineering, fragment screening and molecular modeling, with medicinal chemistry, to help enable success in

novel drug discovery programs against highly-challenging targets. Ab Initio™ technology and services for the design and preparation of customized antigens enable the successful discovery of therapeutic antibodies against difficult-to-access cellular targets. Ligand has established multiple alliances, licenses and other business relationships with the world's leading pharmaceutical companies including Amgen, Merck, Pfizer, Sanofi, Janssen, Takeda, Servier, Gilead Sciences and Baxter International. For more information, please visit [www.ligand.com](http://www.ligand.com).

Follow Ligand on Twitter @Ligand\_LGND.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20200716006031/en/>

Ligand Pharmaceuticals Incorporated

Patrick O'Brien

Email: [investors@ligand.com](mailto:investors@ligand.com)

Phone: (858) 550-7893

Twitter: @Ligand\_LGND

LHA Investor Relations

Bruce Voss

Email: [bvoss@lhai.com](mailto:bvoss@lhai.com)

Phone: (310) 691-7100

Source: Ligand Pharmaceuticals Incorporated